Founded 2016 · Kingdom of Saudi Arabia

Localizing biomanufacturing to secure biologics for Saudi Arabia

Developing top talent and accelerating sector growth in line with Saudi Vision 2030 and the National Biotechnology Strategy.

What we do → Our facility

2016Founded

21Strategic partners

3Business divisions

2027GMP target · Jeddah

Why SVAX exists

A chronic gap in local discovery, development and manufacturing capability.

The world faces a significant unmet need for biologics and biosimilars. In the member countries of the Organization of Islamic Cooperation the challenge is sharper still — limited access to therapies built for global markets, and few solutions for local health challenges the global industry overlooks.

As a member of the G20, Saudi Arabia is uniquely positioned to lead. SVAX exists to close that gap — to build sovereign capability across the biologics value chain, and to develop the national talent that will run it.

Prof. Mazen Hassanain · Chief Executive Officer

The value chain

From development to the released vial

SVAX runs development, fill-finish, quality release and registration inside the Kingdom, and works with partners upstream for drug substance. The aim is a chain that closes inside the region rather than one that depends on a factory outside it.

Three businesses

Three businesses, one company

Biotech Business

Advanced research and development in biologics and biosimilars. Proprietary programmes built on licensed IP from regional partners, plus co-development across every stage of the drug lifecycle.

→ 02

Manufacturing Business

Development and manufacturing services for biologics — cell line development, process optimization, aseptic fill-finish and packaging, to international regulatory standard.

→ 03

Advisory Business

An SFDA-certified CRO supporting local and international companies entering the Saudi market — preclinical studies, regulatory affairs, and biomanufacturing training that builds national capability.

→

Infrastructure

One facility in Jeddah, built for commercial scale

SVAX is building a single aseptic fill-finish facility in Jeddah. Build-out runs through 2026, with manufacturing readiness targeted for the first quarter of 2027.

2026

Build-out

Construction and equipment installation at the Jeddah site.

Q1 2027

Qualification and licence

Commissioning, cleanroom qualification, and the SFDA site licence.

2027

First production

First commercial batch released to specification.

Jeddah · Under construction

A sterile fill-finish facility, built to international GMP

Isolator-based aseptic filling, automated inspection and grade-controlled cleanrooms. Build-out runs through 2026; commissioning, cleanroom qualification and the SFDA site licence follow, with manufacturing readiness targeted for Q1 2027.

See the facility →